Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia

Kariminia, Amina; Ivison, Sabine; Leung, Vivian M.; Sung, Susanna; Couto, Nicole; Rozmus, Jacob; Rolf, Nina; Narendran, Aru; Dunn, Sandra E.; Reid, Gregor S. D.; Schultz, Kirk R.

doi:10.3892/ol.2016.5437

Cited by 8 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… MEK1—YB1: median L R P a u score 0.68. ↦ Interaction has been shown for acute lymphatic leukemia 31 and colorectal cancer 32 . S6—YB1: median L R P a u scores 1.04/0.67.…”

Section: Resultsmentioning

confidence: 99%

Patient-level proteomic network prediction by explainable artificial intelligence

et al. 2022

View full text Add to dashboard Cite

Understanding the pathological properties of dysregulated protein networks in individual patients’ tumors is the basis for precision therapy. Functional experiments are commonly used, but cover only parts of the oncogenic signaling networks, whereas methods that reconstruct networks from omics data usually only predict average network features across tumors. Here, we show that the explainable AI method layer-wise relevance propagation (LRP) can infer protein interaction networks for individual patients from proteomic profiling data. LRP reconstructs average and individual interaction networks with an AUC of 0.99 and 0.93, respectively, and outperforms state-of-the-art network prediction methods for individual tumors. Using data from The Cancer Proteome Atlas, we identify known and potentially novel oncogenic network features, among which some are cancer-type specific and show only minor variation among patients, while others are present across certain tumor types but differ among individual patients. Our approach may therefore support predictive diagnostics in precision oncology by inferring “patient-level” oncogenic mechanisms.

show abstract

“… MEK1—YB1: median L R P a u score 0.68. ↦ Interaction has been shown for acute lymphatic leukemia 31 and colorectal cancer 32 . S6—YB1: median L R P a u scores 1.04/0.67.…”

Section: Resultsmentioning

confidence: 99%

Patient-level proteomic network prediction by explainable artificial intelligence

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Our results indicated that YBX-1 and IL-6 had significantly higher sensitivity and specificity than CA 15-3 which implies their potential role as prognostic markers for breast cancer. The prognostic role of YBX-1 and IL-6 has been referred to in a number of previous studies on various types of cancers including ovarian [36], prostate [37], acute lymphoblastic leukemia [38] and multiple myeloma [39]. However, most of these studies focused on analysis of either fresh or paraffin-imbedded tissues with few exceptions which focused on minimally invasive samples like serum or plasma [35] [40].…”

Section: Discussionmentioning

confidence: 99%

Serum Y-Box Binding Protein 1 (YBX-1) and Interleukin 6 (IL-6) Are Associated with Metastasis in Breast Cancer Patients

Abd-Elaziz¹,

Moneim²,

Fek³

et al. 2019

ABCR

View full text Add to dashboard Cite

Objectives: The aim of this study was to assess the levels of Y-box binding protein 1 (YBX-1) and interleukin 6 (IL-6) in the sera of metastatic and non-metastatic breast cancer patients (BC), investigate their clinicopathological significance and to analyze their potential use as biomarkers of breast cancer metastasis. Methods: The study included ninety subjects sub-grouped equally into metastatic BC, non-metastatic BC and healthy volunteers. Serum YBX-1 and IL-6 were quantified using ELISA technique while CA 15-3 was quantified using IRMA kit. Clinical data were collected from patients' records. Results: YBX-1 (p < 0.001), IL-6 (p < 0.001) and CA15-3 (p = 0.017, 0.001) were significantly elevated in metastatic and non-metastatic BC patients compared to healthy controls, however, only YBX-1 (p < 0.001) and IL-6 (p < 0.001) showed a significant difference with cancer metastasis. Generally, YBX-1 and IL-6 were correlated with worse histological grade and late clinical stage in breast cancer patients and they were also associated with axillary lymph nodes involvement and positive vascular invasion in metastatic BC patients. Serum YBX-1 and IL-6 levels were positively correlated to each other (r s = 0.615, p < 0.001) and they showed high sensitivity and specificity compared to CA 15-3 (p < 0.001 and p = 0.004 for YBX-1 and IL-6 respectively) for predicting cancer metastasis. Conclusions: Serum YBX-1 and IL-6 are potential biomarkers of breast cancer patients with significant correlation with bad clinicopathological characteristics. Serum YBX-1 and IL-6 have superior sensitivity and specificity compared to CA15-3 and can serve as potential follow up and prognostic markers.

show abstract

“…Additionally, IL-7 withdrawal blocks the activation of P38 and JNK kinases, leading to IL-7-dependent thymocyte death [ 71 ]. IL-7 rescues rapamycin-induced apoptosis of B-cell precursor acute lymphoblastic leukemia-acute lymphoblastic leukemia (ALL) cells by upregulating MEK/ERK [ 72 ]. Hence, the MAPK pathway may play a vital role in regulating cell development via IL-7-mediated signal transduction.…”

Section: Biology and Functions Of Il-7 And Il-7rmentioning

confidence: 99%

The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy

Wang

Kong

Kim

et al. 2022

IJMS

View full text Add to dashboard Cite

Interleukin-7 (IL-7) is a multipotent cytokine that maintains the homeostasis of the immune system. IL-7 plays a vital role in T-cell development, proliferation, and differentiation, as well as in B cell maturation through the activation of the IL-7 receptor (IL-7R). IL-7 is closely associated with tumor development and has been used in cancer clinical research and therapy. In this review, we first summarize the roles of IL-7 and IL-7Rα and their downstream signaling pathways in immunity and cancer. Furthermore, we summarize and discuss the recent advances in the use of IL-7 and IL-7Rα as cancer immunotherapy tools and highlight their potential for therapeutic applications. This review will help in the development of cancer immunotherapy regimens based on IL-7 and IL-7Rα, and will also advance their exploitation as more effective and safe immunotherapy tools.

show abstract

Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia

Cited by 8 publications

References 49 publications

Patient-level proteomic network prediction by explainable artificial intelligence

Patient-level proteomic network prediction by explainable artificial intelligence

Serum Y-Box Binding Protein 1 (YBX-1) and Interleukin 6 (IL-6) Are Associated with Metastasis in Breast Cancer Patients

The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy

Contact Info

Product

Resources

About